Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

Introduction: The standard of care for patients with locally-advanced head and neck cancer
is chemoradiation or surgical resection followed by radiation treatment with or without …

The treatment of locoregionally advanced squamous cell carcinoma of the head and neck
(SCCHN) has evolved in recent years as a consequence of a better understanding of the …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been
shown to enhance the effects of radiotherapy, and reports to date indicate that this effect …

The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …